Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Bexarotene - a novel modulator of AURKA and the primary cilium in VHL-deficient cells.

Chowdhury P, Powell RT, Stephan C, Uray IP, Talley T, Karki M, Tripathi DN, Park YS, Mancini MA, Davies P, Dere R.

J Cell Sci. 2018 Dec 14;131(24). pii: jcs219923. doi: 10.1242/jcs.219923.

2.

Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia.

Leipold DD, Figueroa I, Masih S, Latifi B, Yip V, Shen BQ, Dere RC, Carrasco-Triguero M, Lee MV, Saad OM, Liu L, He J, Su D, Xu K, Vuillemenot BR, Laing ST, Schutten M, Kozak KR, Zheng B, Polson AG, Kamath AV.

MAbs. 2018 Nov-Dec;10(8):1312-1321. doi: 10.1080/19420862.2018.1517565. Epub 2018 Oct 2.

3.

SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma.

Chiang YC, Park IY, Terzo EA, Tripathi DN, Mason FM, Fahey CC, Karki M, Shuster CB, Sohn BH, Chowdhury P, Powell RT, Ohi R, Tsai YS, de Cubas AA, Khan A, Davis IJ, Strahl BD, Parker JS, Dere R, Walker CL, Rathmell WK.

Cancer Res. 2018 Jun 15;78(12):3135-3146. doi: 10.1158/0008-5472.CAN-17-3460. Epub 2018 May 3.

PMID:
29724720
4.

Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL.

Hasanov E, Chen G, Chowdhury P, Weldon J, Ding Z, Jonasch E, Sen S, Walker CL, Dere R.

Oncogene. 2017 Jun 15;36(24):3450-3463. doi: 10.1038/onc.2016.495. Epub 2017 Jan 23.

5.

Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.

Fuh FK, Looney C, Li D, Poon KA, Dere RC, Danilenko DM, McBride J, Reed C, Chung S, Zheng B, Mathews WR, Polson A, Prabhu S, Williams M.

Br J Pharmacol. 2017 Apr;174(8):628-640. doi: 10.1111/bph.13697. Epub 2017 Mar 6.

6.

Integrated Two-Analyte Population Pharmacokinetic Model for Antibody-Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling.

Lu D, Gibiansky L, Agarwal P, Dere RC, Li C, Chu YW, Hirata J, Joshi A, Jin JY, Girish S.

CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):665-673. doi: 10.1002/psp4.12137. Epub 2016 Nov 10.

7.

Methylated α-tubulin antibodies recognize a new microtubule modification on mitotic microtubules.

Park IY, Chowdhury P, Tripathi DN, Powell RT, Dere R, Terzo EA, Rathmell WK, Walker CL.

MAbs. 2016 Nov/Dec;8(8):1590-1597. Epub 2016 Sep 3.

8.

Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

Advani RH, Lebovic D, Chen A, Brunvand M, Goy A, Chang JE, Hochberg E, Yalamanchili S, Kahn R, Lu D, Agarwal P, Dere RC, Hsieh HJ, Jones S, Chu YW, Cheson BD.

Clin Cancer Res. 2017 Mar 1;23(5):1167-1176. doi: 10.1158/1078-0432.CCR-16-0772. Epub 2016 Sep 6.

9.

Dual Chromatin and Cytoskeletal Remodeling by SETD2.

Park IY, Powell RT, Tripathi DN, Dere R, Ho TH, Blasius TL, Chiang YC, Davis IJ, Fahey CC, Hacker KE, Verhey KJ, Bedford MT, Jonasch E, Rathmell WK, Walker CL.

Cell. 2016 Aug 11;166(4):950-962. doi: 10.1016/j.cell.2016.07.005.

10.

A new role for ATM in selective autophagy of peroxisomes (pexophagy).

Tripathi DN, Zhang J, Jing J, Dere R, Walker CL.

Autophagy. 2016;12(4):711-2. doi: 10.1080/15548627.2015.1123375.

11.

Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity.

McCampbell AS, Mittelstadt ML, Dere R, Kim S, Zhou L, Djordjevic B, Soliman PT, Zhang Q, Wei C, Hursting SD, Lu KH, Broaddus RR, Walker CL.

Curr Mol Med. 2016;16(3):252-65.

12.

ATM functions at the peroxisome to induce pexophagy in response to ROS.

Zhang J, Tripathi DN, Jing J, Alexander A, Kim J, Powell RT, Dere R, Tait-Mulder J, Lee JH, Paull TT, Pandita RK, Charaka VK, Pandita TK, Kastan MB, Walker CL.

Nat Cell Biol. 2015 Oct;17(10):1259-1269. doi: 10.1038/ncb3230. Epub 2015 Sep 7.

13.

Aminothiazoles: Hit to lead development to identify antileishmanial agents.

Bhuniya D, Mukkavilli R, Shivahare R, Launay D, Dere RT, Deshpande A, Verma A, Vishwakarma P, Moger M, Pradhan A, Pati H, Gopinath VS, Gupta S, Puri SK, Martin D.

Eur J Med Chem. 2015 Sep 18;102:582-93. doi: 10.1016/j.ejmech.2015.08.013. Epub 2015 Aug 11.

PMID:
26318065
14.

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F.

Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27.

PMID:
25925619
15.

Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys.

Lu D, Jin JY, Girish S, Agarwal P, Li D, Prabhu S, Dere RC, Saad OM, Nazzal D, Koppada N, Ramanujan S, Ng CM.

Pharm Res. 2015 Jun;32(6):1907-19. doi: 10.1007/s11095-014-1585-y. Epub 2014 Dec 3.

16.

β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma.

Dere R, Perkins AL, Bawa-Khalfe T, Jonasch D, Walker CL.

J Am Soc Nephrol. 2015 Mar;26(3):553-64. doi: 10.1681/ASN.2013090984. Epub 2014 Oct 13.

17.

Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.

Gopinath VS, Pinjari J, Dere RT, Verma A, Vishwakarma P, Shivahare R, Moger M, Kumar Goud PS, Ramanathan V, Bose P, Rao MV, Gupta S, Puri SK, Launay D, Martin D.

Eur J Med Chem. 2013 Nov;69:527-36. doi: 10.1016/j.ejmech.2013.08.028. Epub 2013 Sep 15.

PMID:
24095747
18.

A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS.

Zhang J, Kim J, Alexander A, Cai S, Tripathi DN, Dere R, Tee AR, Tait-Mulder J, Di Nardo A, Han JM, Kwiatkowski E, Dunlop EA, Dodd KM, Folkerth RD, Faust PL, Kastan MB, Sahin M, Walker CL.

Nat Cell Biol. 2013 Oct;15(10):1186-96. doi: 10.1038/ncb2822. Epub 2013 Aug 18.

19.

Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum.

Xu K, Liu L, Dere R, Mai E, Erickson R, Hendricks A, Lin K, Junutula JR, Kaur S.

Bioanalysis. 2013 May;5(9):1057-71. doi: 10.4155/bio.13.66.

PMID:
23641696
20.

PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.

Dere R, Yi JH, Lei C, Saad OM, Huang C, Li Y, Baudys J, Kaur S.

Bioanalysis. 2013 May;5(9):1025-40. doi: 10.4155/bio.13.72.

PMID:
23641694
21.

Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.

Carrasco-Triguero M, Yi JH, Dere R, Qiu ZJ, Lei C, Li Y, Mahood C, Wang B, Leipold D, Poon KA, Kaur S.

Bioanalysis. 2013 May;5(9):1007-23. doi: 10.4155/bio.13.64.

PMID:
23641693
22.

DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.

Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG.

Mol Cancer Ther. 2013 Jul;12(7):1255-65. doi: 10.1158/1535-7163.MCT-12-1173. Epub 2013 Apr 18.

23.

Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.

Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguero M.

Bioanalysis. 2013 Jan;5(2):201-26. doi: 10.4155/bio.12.299. Erratum in: Bioanalysis. 2013 Mar;5(6):741. Bioanalysis. 2013 Nov;5(21):2734.

PMID:
23330562
24.

Differential expression of SUMO-specific protease 7 variants regulates epithelial-mesenchymal transition.

Bawa-Khalfe T, Lu LS, Zuo Y, Huang C, Dere R, Lin FM, Yeh ET.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17466-71. doi: 10.1073/pnas.1209378109. Epub 2012 Oct 8.

25.

Synthesis of α-glycosyl thiols by stereospecific ring-opening of 1,6-anhydrosugars.

Zhu X, Dere RT, Jiang J, Zhang L, Wang X.

J Org Chem. 2011 Dec 16;76(24):10187-97. doi: 10.1021/jo202069y. Epub 2011 Nov 16.

PMID:
22059806
26.

Synthesis of glycosylthiols and reactivity studies.

Dere RT, Kumar A, Kumar V, Zhu X, Schmidt RR.

J Org Chem. 2011 Sep 16;76(18):7539-45. doi: 10.1021/jo200624e. Epub 2011 Aug 22.

PMID:
21800823
27.

Glycoside bond formation via acid-base catalysis.

Kumar A, Kumar V, Dere RT, Schmidt RR.

Org Lett. 2011 Jul 15;13(14):3612-5. doi: 10.1021/ol201231v. Epub 2011 Jun 15.

PMID:
21675711
28.

Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.

Hogan AE, O'Reilly V, Dunne MR, Dere RT, Zeng SG, O'Brien C, Amu S, Fallon PG, Exley MA, O'Farrelly C, Zhu X, Doherty DG.

Clin Immunol. 2011 Aug;140(2):196-207. doi: 10.1016/j.clim.2011.03.016. Epub 2011 Apr 13.

PMID:
21493160
29.

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.

Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, McBride J, Raab H, Januario T, Go M, Lau J, Yu SF, Du C, Fuh F, Tan C, Wu Y, Liang WC, Prabhu S, Stephan JP, Hongo JA, Dere RC, Deng R, Cullen M, de Tute R, Bennett F, Rawstron A, Jack A, Ebens A.

Leukemia. 2010 Sep;24(9):1566-73. doi: 10.1038/leu.2010.141. Epub 2010 Jul 1.

PMID:
20596033
30.

Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR.

Dere R, Wilson PD, Sandford RN, Walker CL.

PLoS One. 2010 Feb 16;5(2):e9239. doi: 10.1371/journal.pone.0009239.

31.

AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability.

Short JD, Dere R, Houston KD, Cai SL, Kim J, Bergeron JM, Shen J, Liang J, Bedford MT, Mills GB, Walker CL.

Mol Carcinog. 2010 May;49(5):429-39. doi: 10.1002/mc.20613.

32.

Synthesis of beta-D-arabinofuranosides: stereochemical differentiation between D- and L-enantiomers.

Wang Y, Maguire-Boyle S, Dere RT, Zhu X.

Carbohydr Res. 2008 Dec 8;343(18):3100-6. doi: 10.1016/j.carres.2008.09.006. Epub 2008 Sep 10.

PMID:
18809174
33.

The first synthesis of a thioglycoside analogue of the immunostimulant KRN7000.

Dere RT, Zhu X.

Org Lett. 2008 Oct 16;10(20):4641-4. doi: 10.1021/ol8019555. Epub 2008 Sep 23.

PMID:
18808135
34.

AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27.

Short JD, Houston KD, Dere R, Cai SL, Kim J, Johnson CL, Broaddus RR, Shen J, Miyamoto S, Tamanoi F, Kwiatkowski D, Mills GB, Walker CL.

Cancer Res. 2008 Aug 15;68(16):6496-506. doi: 10.1158/0008-5472.CAN-07-5756.

35.

A direct and stereospecific approach to the synthesis of alpha-glycosyl thiols.

Dere RT, Wang Y, Zhu X.

Org Biomol Chem. 2008 Jun 21;6(12):2061-3. doi: 10.1039/b804536d. Epub 2008 Apr 30.

PMID:
18528566
36.

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY.

J Clin Oncol. 2006 Sep 10;24(26):4324-32. Epub 2006 Aug 8. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793.

PMID:
16896006
37.
38.

Advances in mechanisms of genetic instability related to hereditary neurological diseases.

Wells RD, Dere R, Hebert ML, Napierala M, Son LS.

Nucleic Acids Res. 2005 Jul 8;33(12):3785-98. Print 2005. Review.

39.
40.

Structure-dependent recombination hot spot activity of GAA.TTC sequences from intron 1 of the Friedreich's ataxia gene.

Napierala M, Dere R, Vetcher A, Wells RD.

J Biol Chem. 2004 Feb 20;279(8):6444-54. Epub 2003 Nov 18.

41.

Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers.

Ramakrishnan V, Sinicropi DV, Dere R, Darbonne WC, Bechtol KB, Baker JB.

J Biol Chem. 1990 Feb 15;265(5):2755-62.

Supplemental Content

Support Center